Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Mar 1.

Published in final edited form as: Ann Emerg Med. 2021 Nov 19;79(3):225–236. doi: 10.1016/j.annemergmed.2021.10.005

Figure 3. — Naloxone and buprenorphine prescribing after ED visits for opioid overdose during August 4, 2019-April 3, 2021, Symphony Health Integrated Dataverse. A) Naloxone; B) Buprenorphine. The red line represents the weekly proportion of ED visits with ≥1 prescription (pharmacy claim) for the drug within 30 days, regardless of whether the medication was dispensed. The blue line represents the weekly proportion of ED visits with ≥1 dispensed prescription (paid pharmacy claim) for the drug during the 90 days to 1 day prior to the visit, regardless of whether the drug was prescribed within 30 days. We assessed the latter proportion to evaluate the degree to which prescribing after visits may have been influenced by the existence of prior prescriptions.

Figure 3. — Naloxone and buprenorphine prescribing after ED visits for opioid overdose during August 4, 2019-April 3, 2021, Symphony Health Integrated Dataverse. A) Naloxone; B) Buprenorphine. The red line represents the weekly proportion of ED visits with ≥1 prescription (pharmacy claim) for the drug within 30 days, regardless of whether the medication was dispensed. The blue line represents the weekly proportion of ED visits with ≥1 dispensed prescription (paid pharmacy claim) for the drug during the 90 days to 1 day prior to the visit, regardless of whether the drug was prescribed within 30 days. We assessed the latter proportion to evaluate the degree to which prescribing after visits may have been influenced by the existence of prior prescriptions.